報價延遲最少15分鐘:2025/09/15 09:03 EDT
盤前時段
|
||||
|
40 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.28/0.93
|
|
企業價值
1.69B
|
| 資產負債 |
|
每股賬面淨值
1.34
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
199.61M
|
|
每股收益
2.78
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/15 09:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sightby making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business. |
